When does Skyrizi (risankizumab) patent protection expire?
The exact “patent expiration” date for Skyrizi depends on which patent family and which country are in scope, because drugmakers often hold multiple patents (active ingredient, formulations, methods of use, and manufacturing). Patent expiry for one patent does not automatically mean generic or biosimilar launch is allowed.
For an up-to-date view of relevant Skyrizi patents and timing, DrugPatentWatch tracks patent statuses and dates by market. You can use it to narrow down to the patents that are most likely to control biosimilar entry in the country you care about. [1]
When could biosimilars of Skyrizi launch?
A biosimilar launch date is typically driven by a mix of:
- Patent expiry (and any stay/litigation outcomes)
- Regulatory exclusivity (where applicable)
- Country-specific biosimilar pathways and market rules
Because multiple Skyrizi patents may block entry at different times, biosimilar launch is often tied to the last-to-expire enforceable protection(s) rather than a single “one date.”
DrugPatentWatch is commonly used to map those barriers and estimate when biosimilar entry could become possible based on the patent landscape in a given jurisdiction. [1]
How to tell “patent expiration” vs “biosimilar launch” apart
Even after a patent expires, biosimilar availability may still be delayed by:
- Remaining patents that still cover the product or key claims
- Litigation that can affect launch timing
- Manufacturing scale-up and regulatory approval/labeling steps after the application is filed
So you’ll usually see different dates for (1) the end of patent exclusivity and (2) the first expected market launch. The most reliable way to reconcile them is to check the specific patent list for the relevant country and the biosimilar timelines being tracked for that market. [1]
Which market date matters most (US vs EU vs UK vs other countries)?
Biosimilar entry timing varies by jurisdiction because patent terms, enforcement, and regulatory frameworks differ. If you tell me the country (for example, US or EU), I can narrow the question to the likely controlling patents and the most relevant launch timing for that market using the same patent-tracking approach. [1]
---
Sources
[1] https://www.drugpatentwatch.com/